BOOMING MOBILE HEALTH APP MARKET NEEDS ROBUST FDA OVERSIGHT TO ENSURE CONSUMER SAFETY, CONFIDENCE Health Law Experts in July 24 New England Journal of Medicine Smart phones and mobile devices are on the cusp of revolutionizing health care, armed ... RF Globalnet, 4 hours ago
Booming mobile health app market needs more FDA oversight for consumer safety, confidence - ECN, 2 days ago
Is That App FDA Approved? Mobile Health Tech Falls Into Gray Area - Mashable, 12 hours ago
Erasmus Medical Center says it has wrapped up its investigation of Don Poldermans, the disgraced cardiology researcher who was fired for research misconduct. The full extent of the misconduct has never been known, and from an examination of the ...Forbes.com, 15 hours ago
by the non-partisan and insanely prestigious New England Journal of Medicine, the Affordable Care Act has brought health insurance to some 20 million people. Let's hope they all vote come November. And, why was this not front page news everywhere? ...National Catholic Reporter, 2 days ago Study finds 10.3M gained insurance through health law The Hill, 1 week ago More Than 10 Million People Gained Coverage Under Obamacare, Study Finds MedicineNet.com, 5 days ago New England Journal of Medicine: 20 Million Now Covered Under Obamacare Daily Kos, 1 week ago
In a new paper, published July 10 in the New England Journal of Medicine, researchers analyzed previous studies on antioxidants and cancer, trying to determine why taking antioxidants hasn't seemed to reduce people's cancer risk. The authors of the ...Business Insider, 5 days ago Antioxidant Supplements Don't Fight Cancer, Research Suggests Huffington Post, 6 days ago
New England Journal of Medicine Publishes Ipsen's Somatuline® CLARINET® Phase III Results in Patients with Metastatic Gastroenteropancreatic...
New England Journal of Medicine Publishes Ipsen's Somatuline® CLARINET® Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors By a News Reporter-Staff News Editor at Clinical Trials Week -- The U.S.4 Traders, 1 week ago Le New England Journal of Medicine publie les résultats de létude de phase III Clarinet® dIpsen avec Somatuline® chez des patients atteints de tumeurs métastatiques neuro-endocrines gastro-entéro-pancréatiques Business Wire, 2 weeks ago Study raises hope for young breast cancer patients Times of India, 1 month ago
Large Majority of Patients Who Need Unrelated Bone Marrow Transplants Can Find a Matching Donor on the National Be The Match Registry®
Study published in New England Journal of Medicine highlights the far-reaching impact the registry has on patients with blood cancer and other life-threatening diseases MINNEAPOLIS--(BUSINESS WIRE)-- An overwhelming percentage of patients who ...CNBC, 6 days ago Patients Very Likely to Find a Suitable Bone Marrow Donor on the National Marrow Donor Registry Navy News Stand, 2 days ago
The findings in the New England Journal of Medicine show a "significant" decline in the uninsured rate for adults aged 18 to 64 GETTING HEALTH CARE. Screenshot of Healthcare.gov. WASHINGTON DC, USA More than 10 million uninsured people in the ...Rappler, 1 week ago Study Finds 10.3M Uninsured Gained Coverage Under ACA FOXBusiness.com, 1 week ago Study: Obamacare enabled 10.3 million uninsured Americans to get coverage Los Angeles Business, 1 week ago
Boni Elewski, M.D., led one of two trials featured in the New England Journal of Medicine that show secukinumab is a safe and effective psoriasis treatment. Randomized, phase III re from the University of Alabama at Birmingham shows that a new ...Noodls, 1 week ago New psoriasis drug shows potential Science Daily, 1 week ago Phase III research shows that new drug improves symptoms related to plaque psoriasis News-Medical.Net, 2 weeks ago
A new study published in the New England Journal of Medicine suggests that prison inmates in the US can prove to be a potent weapon in the fight against hepatitis C virus infection as more than 16 percent of prisoners are infected with the virus and can be ...Med India, 2 months ago
EMA Approves Eisai's Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer
From the Wires Jul. 30, 2014 07:01 PM HATFIELD, England , July 31, 2014 /PRNewswire/ -- FOR EU MEDIA ONLY: NOT FOR SWISS MEDIA Accelerated Review Demonstrates the Importance of Lenvatinib for This Therapeutic Area The European ...Sys-Con India, 6 hours ago
on your WebpageAdd Widget >Get your members hooked!